Many patients who were offered a metal-on-metal hip replacement implant were sold on the benefits of the device: greater durability and longevity. Now, many of those patients are facing the exact opposite: increased failure rates and complications that just aren’t present in traditional hip implants.
Even though it seems a bit “too little, too late”, the FDA is increasingly involved in dealing with the aftermath of these faulty medical devices. Most recently, at the end of June, the agency held a two-day advisory committee meeting to discuss metal-on-metal hip systems. Specifically, the meeting was focused on the current knowledge about the safety and effectiveness of Metal-on-Metal (MoM) hip arthroplasty systems and sought expert scientific and clinical opinion on the risks and benefits of these types of devices based on available scientific data.
A number of scientific studies provide the background for the advisory committee meeting and the need to address safety concerns related to metal-on-metal devices. Those studies have shown increased failure rates of the metal-on-metal systems at only the five year mark, which in turn requires patients to undergo revision surgery. Studies have also highlighted a risk of metallosis as the friction between the metal components in the implant releases small metal particles into the blood stream.
The advisory committee was tasked with examining: device mechanisms of failure, metal ion testing, imaging methods, local and systemic complications, preoperative and postoperative patient risk factors, as well as clinical follow-up considerations for patients with metal-on-metal hip systems.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.